Dasatinib + Methotrexate + Prednisone + Rituximab + Venetoclax + Blinatumomab
Phase 1RecruitingDevelopment Stage
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Sep 2, 2022 → Dec 2, 2026
About Dasatinib + Methotrexate + Prednisone + Rituximab + Venetoclax + Blinatumomab
Dasatinib + Methotrexate + Prednisone + Rituximab + Venetoclax + Blinatumomab is a phase 1 stage product being developed by AbbVie for B Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04872790. Target conditions include B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04872790 | Phase 1 | Recruiting |
Competing Products
20 competing products in B Acute Lymphoblastic Leukemia